Specialty Software Deals Continue Reshaping Chemical R&D Digitalization

Introduction

The chemical and pharmaceutical industries are entering a new phase of digital transformation in which specialized scientific software is becoming a strategic asset rather than simply an IT tool. Companies are increasingly looking for platforms that can connect laboratory data, analytical characterization, molecular design, experimentation, and manufacturing decisions.

This shift is also influencing the M&A landscape. Recent transactions and partnerships involving scientific software providers show how larger technology and life sciences companies are seeking specialized capabilities that can accelerate digital R&D and prepare organizations for wider adoption of artificial intelligence.

The acquisition of ACD/Labs by Revvity is one of the clearest examples of this trend, bringing analytical characterization and molecular-design capabilities into Revvity Signals.

Why Chemical R&D Software Is Becoming Strategic

Chemical R&D generates highly complex datasets from spectroscopy, molecular structures, formulations, experiments, simulations, and quality testing. Historically, much of this information has remained distributed across different instruments, databases, spreadsheets, and laboratory systems.

As companies move toward digital R&D, they increasingly need software that can bring these datasets together and make them searchable, reusable, and suitable for advanced analytics and AI.

ACD/Labs' recent research on R&D digitalization highlights this transition, noting that organizations have made progress in digitizing information but still face challenges in effectively using that data across workflows.

This creates an opportunity for specialized software providers with deep domain knowledge in chemistry and analytical science.

Revvity’s ACD/Labs Acquisition Highlights the Trend

In November 2025, Revvity announced an agreement to acquire ACD/Labs, a provider of scientific software for analytical characterization and molecular design across pharmaceutical and materials science markets. The deal was designed to strengthen Revvity Signals and help connect analytical data with actionable scientific insights.

ACD/Labs brings several specialized platforms to Revvity, including Spectrus for advanced spectral analysis and Percepta for molecular property and ADMET prediction. Its portfolio also includes tools supporting high-throughput experimentation, pharmaceutical chemistry, manufacturing decision support, and enterprise analytical data management.

The strategic value of the deal lies in combining these specialized capabilities with a broader research informatics platform.

From Individual Tools to End-to-End R&D Platforms

The software market is moving away from isolated applications toward more connected scientific ecosystems.

For chemical companies, an ideal digital workflow can link:

• Molecular design

• Experiment planning

• Laboratory data capture

• Analytical characterization

• Data management

• Predictive modeling

• Formulation development

• Scale-up

• Manufacturing and quality control

Revvity has positioned its ACD/Labs acquisition around exactly this type of integration, with the combined technology intended to support workflows from discovery and development through scale-up and manufacturing.

This approach can reduce data fragmentation and make scientific information more useful across different teams.

AI Is Increasing the Value of Scientific Data

Artificial intelligence is adding another layer to the digitalization story.

AI models require reliable, structured, and contextualized data to generate useful predictions and recommendations. In chemical R&D, this means organizations need more than large quantities of data—they need high-quality chemical, analytical, structural, and experimental information.

ACD/Labs has already incorporated AI into products such as Percepta, while collaborations such as its work with Covestro have demonstrated how AI can be applied to practical chemical research problems such as solvent selection.

This illustrates why software companies with specialized scientific datasets and domain-specific algorithms are becoming increasingly attractive acquisition targets.

The Rise of Specialized R&D Informatics

The market is also expanding beyond traditional electronic laboratory notebooks and basic data-management systems.

Modern R&D platforms increasingly combine data capture, analytics, predictive modeling, workflow automation, and AI. Revvity Signals, for example, describes its chemicals and materials solutions as a unified platform for capturing, organizing, and analyzing formulation and specialty chemical data.

For specialty chemical manufacturers, these capabilities can support applications ranging from coatings and adhesives to catalysts, polymers, electronic chemicals, surfactants, and advanced materials.

The broader opportunity is to turn historical R&D information into reusable organizational knowledge.

Why Acquisitions Make Sense for Larger Companies

Building specialized chemical software capabilities internally can take years. It requires software engineers, data scientists, chemists, analytical experts, and knowledge of highly specific laboratory workflows.

Acquisitions provide a faster route to obtaining these capabilities.

A software company with an established customer base, mature products, proprietary algorithms, and scientific expertise can immediately add capabilities that would otherwise take significant time and investment to develop.

For larger life sciences and technology companies, acquisitions can therefore accelerate the expansion of their digital R&D portfolios.

Chemical Companies Are Looking Beyond Basic Digitalization

The next stage of chemical R&D digitalization is increasingly focused on decision intelligence rather than simply storing information.

A digitally connected R&D environment can help scientists answer questions such as:

• Which previous experiments are relevant to a new formulation?

• How does molecular structure influence performance?

• Which analytical results indicate a quality issue?

• Which formulation variables should be tested next?

• Can an experiment be optimized before it reaches the laboratory?

• How can historical R&D knowledge be reused across projects?

These capabilities can potentially reduce duplicated experimentation, improve knowledge transfer, and shorten development cycles.

Data Quality Becomes a Competitive Advantage

As companies adopt AI and predictive modeling, the quality of their scientific data becomes increasingly important.

Chemical R&D data can contain different formats, naming conventions, structures, units, analytical methods, and metadata. Without appropriate standardization and context, valuable information can remain effectively inaccessible.

This is why specialized scientific software providers have an advantage: they understand the structure and meaning of chemical and analytical information rather than treating it as generic enterprise data.

The combination of scientific expertise and software engineering is becoming a critical part of the digital R&D value chain.

Implications for Specialty Chemical Manufacturers

For specialty chemical producers, digital R&D platforms can provide benefits beyond laboratory efficiency.

Better access to historical formulation and performance data can support faster product development, improved formulation optimization, and stronger knowledge retention. Predictive analytics can also help teams evaluate potential formulations before committing resources to extensive physical testing.

As competition increases around product performance, sustainability, cost, and speed to market, digital R&D capabilities could become an increasingly important competitive differentiator.

What the M&A Trend Could Mean for the Market

The growing interest in specialty scientific software could lead to further consolidation across the chemical R&D technology landscape.

Potential acquisition targets may include companies specializing in:

• Chemical informatics

• Analytical data management

• Molecular modeling

• Laboratory automation

• Formulation optimization

• Digital experimentation

• Process development

• AI-powered chemical prediction

• Scientific workflow management

For software providers, strategic partnerships and acquisitions can provide access to larger customer networks and additional development resources. For buyers, they can accelerate the transition toward integrated digital R&D platforms.

Conclusion

Specialty software is becoming an increasingly important component of chemical and pharmaceutical R&D strategy. The acquisition of ACD/Labs by Revvity demonstrates how established life sciences companies are using M&A to strengthen their analytical, molecular, and informatics capabilities.

The broader trend is moving the industry from fragmented digital tools toward integrated, AI-ready R&D ecosystems that connect experimental data, analytical characterization, molecular intelligence, and manufacturing workflows.

As chemical companies continue their digital transformation, software that understands the science behind the data could become just as strategically important as the physical laboratory infrastructure itself. Future specialty software deals are therefore likely to play a significant role in determining how quickly chemical R&D organizations can move toward more connected, automated, and data-driven innovation.